Kornimate/medical-research-clean huggingface dataset:
erector spinae vs fascia iliaca block in hip arthroplasty

Conditions: Pain, Postoperative

Summary: the thoracic erector spinae plane (esp) block was first described by forero et al in september 2016. in their article, the authors presented the possibility of using this block as an option for the control of thoracic neuropathic pain as well as post-operative thoracic pain. the esp block is done by administering local anesthetic in the plane deep to the erector spinae muscle, which spreads through the costotransverse foramen to the dorsal and ventral roots of the spinal nerves. since then, there have been reports about the successful use of this block for bariatric surgery, ventral hernia repair, radical mastectomy, rib fractures, major abdominal surgery and hip replacement. however, there are no studies in the literature comparing the efficacy of the esp block to other nerve blocks. the purpose of this study is to compare the post-operative analgesic efficacy of the esp block to the fascia iliaca (fi) block after total hip replacement (thr).


Eligibility criteria:
inclusion criteria: * surgical plan for total hip replacement * signing of consent form to participate in the study exclusion criteria: * patient refusal * bmi \> 40 kg/m2 * surgical plan for revision of hip replacement * patient unable to quantify pain level * chronic kidney disease with a glomerular filtration rate \< 50ml/min * previously medicated with opioids * patient unable to perform the surgery with spinal block * allergy to local anesthetics * infection in the site of the erector spinae plane or fascia iliaca block * allergy or contraindication to the use of morphine

Keywords: hip arthroplasty erector spinae plane block
the effect of resistance training in parkinson disease: a pilot study

Conditions: Parkinson Disease

Summary: to investigate if resistance training exercises performed twice a week with or without gym equipment assistance in a 12-week period could improve balance in patients with parkinson disease (pd). methods: sixty three patients with idiopathic pd (hoehn and yahr stage ii - iii) and preserved cognitive function will participate in this study. patients will be randomized among three intervention groups: resistance training with free weights, resistance training with gym equipment and control group. investigators will use static platform balance variables to assess the primary end-point outcome measures. for the secondary outcomes measures, most common clinical functional balances tests for pd will be applied: berg balance scale (bbs), mini-bestest - balance evaluation (mini-bestest), timed up and go test (tug) and variables from dynamic posturography.

parkinson's disease is a progressive neurodegenerative disease that affects motor functions and is characterized by bradykinesia, resting tremor, rigidity, and postural instability. despite of pharmacological treatments, patients remain with deficits in balance, gait, autonomic system functions and cognition which impact on their quality of life. the effects of resistance training on pd are still controversial when balance and improvement on functional tests are the targets. since the results of previous studies about resistance training on balance are still controversial, more interventions are required to address the question if strengthening exercise may improve or not the balance of pd patients. our exercises will target the trunk, leg and shoulder muscles because of their contribution on patient's posture.

Eligibility criteria:
inclusion criteria: * age between 50 to 75 years old; * hoehn and yahr stages ii or iii; * idiopathic parkinson disease diagnosed according to the united kingdom parkinson's disease society brain research centre criteria, institute of neurology, london; * ability to walk independently without walking devices aid; * absence of orthopedic injuries or pain in joints that could interfere on training program; * stable medication regimen for pd treatment at recruitment stage; * mini mental state examination scale (mmse) ≥ to 27 for literate patients and schooling ≥ of 4 years of formal education; * no cardiovascular instability; * no pacemaker, decompensated metabolic disease, vestibular dysfunction, and stroke; * availability to come to the clinic twice a week; * not participating in other physical rehabilitation programs during and six months prior to the study. exclusion criteria: * patients will be excluded if they refuse to participate, do not sign the consent form, have a diagnosis of secondary parkinsonism or present cognitive impairment.

Keywords: resistance training postural balance exercise
a study of rhinaer arc stylus for treating chronic rhinitis (relief)

Conditions: Chronic Rhinitis

Summary: post-market study to continue to evaluate the effectiveness of the rhinaer arc stylus for chronic rhinitis.

prospective, open label, multicenter study of the aerin medical rhinaer® arc stylus for chronic rhinitis to continue to evaluate the effectiveness of the rhinaer® arc stylus for treating the posterior nasal nerve area to improve symptoms in adults diagnosed with chronic rhinitis.

Eligibility criteria:
inclusion criteria: 1. age 18 to 85 years (inclusively). 2. willing and able to provide informed consent. 3. willing and able to comply with the subject-specific requirements outlined in the study protocol. 4. seeking treatment for chronic rhinitis symptoms of at least 6 months duration and willing to undergo an office-based procedure. 5. moderate to severe symptoms of rhinorrhea (rtnss rating of 2 or 3 for rhinorrhea). 6. mild to severe symptoms of nasal congestion (rtnss rating of 1, 2 or 3 for congestion). 7. rtnss ≥ 6. exclusion criteria: 1. anatomic obstructions that in the investigator's opinion limit access to the posterior nasal passage. 2. altered anatomy of the posterior nose as a result of prior sinus or nasal surgery or injury. 3. active nasal or sinus infection. 4. history of significant dry eye. 5. history of any of the following: chronic epistaxis, documented episodes of significant nose bleeds in the past 3 months, rhinitis medicamentosa, head or neck irradiation. 6. have rhinitis symptoms only on a seasonal basis due to allergies. 7. known or suspected allergies or contraindications to the anesthetic agents and/or antibiotic medications to be used during the study procedure session. 8. known or suspected to be pregnant or is lactating. 9. participating in another clinical research study. 10. has any condition that predisposes to excessive bleeding. 11. is taking anticoagulants (eg, warfarin, plavix) or 325 mg aspirin that cannot be discontinued before the procedure. 12. has previous procedure or surgery for chronic rhinitis. 13. other medical conditions which in the opinion of the investigator would predispose the subject to poor wound healing, increased surgical risk, or poor compliance with the requirements of the study.
the connection between personality, burnout, and hypertension in nigerian bank employees

Conditions: Hypertension

Summary: this is a longitudinal study which we plan to examine the link between personality traits, burnout, and hypertension in bank employees in south-eastern nigeria

this proposed longitudinal study aims to examine the relationship between personality traits, burnout, and hypertension in bank employees in south-eastern nigeria, where hypertension is a significant public health issue. the study will involve bankers as participants, who will be asked to complete self-report questionnaires and measure their blood pressure over four weeks. the research seeks to determine if personality differences and burnout levels contribute to hypertension risk in this population. by understanding the role of psychosocial factors in hypertension risk, the study hopes to provide recommendations for workplace adjustments that could improve employee well-being and reduce hypertension risk among nigerian bank employees.

Eligibility criteria:
inclusion criteria: * any staff of the bank exclusion criteria: * non staff
post market surveillance of the heartmate 3 left ventricular assist system in korea

Conditions: Advanced Heart Failure

Summary: the korea hm3 pms is a prospective, single arm, open-label, multi-center, post market surveillance is designed to evaluate clinical and functional outcomes with the hm3 lvas as a treatment for advanced heart failure. the pms will enroll up to 300 patients, that meet the health insurance review and assessment (hira) guidelines for lvad implantation, from up to 25 sites in south korea. subjects who will be implanted but not included in the pms can be enrolled retrospectively after obtaining their informed consent. the surveillance period for this pms is expected to be 4 years from the time of hm3 approval in korea, concluding on june 2, 2024.


Eligibility criteria:
inclusion criteria general inclusion criteria: all patients approved for hm3 implantation in korea as per hira guidelines will be eligible to be enrolled in the pms. only the patients who provide written informed consent will be included in the study. if a subject has had an outcome after the hm3 implantation but prior to providing informed consent, no consent will be obtained, and a limited anonymized data will be collected. exclusion criteria general exclusion criteria: this post market surveillance does not have specific exclusion criteria

Keywords: heartmate 3 abt-cip-10344 left ventricular assist device
effects and underlying mechanism of lipid lowering intervention on vascular protection in hypertensive patients

Conditions: Hypertension

Summary: the purpose of eminent study is to evaluate the efficacy of xuezhikang or atorvastatin in hypertensive patients at low/moderate cardiovascular risk.

eminent study is to evaluate the efficacy of xuezhikang or atorvastatin on vascular function protection in hypertensive patients at low/moderate cardiovascular risk.

Eligibility criteria:
inclusion criteria: * all patients must meet the hypertension with low or moderate cardiovascular risk following 2010 guidelines for prevention and treatment of hypertension in china exclusion criteria: * secondary hypertension * women who are pregnant or lactating * history of mental instability, or major psychiatric illness not adequately controlled and stable on therapy * type 2 diabetes * active liver disease or impaired liver function tests * impaired renal function * uncontrolled cardiac arrhythmia * patient who is unable to give informed consent * any condition or situation, which in the opinion of the investigator, might pose a risk to the patient or confound the results of the study

Keywords: xuezhikang atorvastatin
dilation and curettage versus operative hysteroscopy for missed abortion

Conditions: Spontaneous Abortion; Missed Abortion; Intrauterine Adhesion; Retained Products of Conception

Summary: randomizedtrial comparing success and complication rates of operative hysteroscopy versus traditional dilation and curettage (d\&c) in the management of first trimester missed abortion.

a randomized controlled trial (rct) of women diagnosed with first trimester spontaneous abortion. participants interested in operative evacuation of the uterus will be randomized to either operative hysteroscopy or dilation an curettage (d\&c). study population will include pregnant women diagnosed with first trimester spontaneous abortion of up to 13+0 weeks from last menstrual period (lmp) or up to 11+0 weeks of gestation as determined by crown-rump length (crl). women who will electively choose to terminate their pregnancy as well as women diagnosed with threatened, incomplete or inevitable abortion will be excluded. all participants will undergo diagnostic hysteroscopy 6-8 weeks after allocated treatment in order to rule out intrauterine adhesion formation and retained product of conception. the primary outcome measure is the risk of intrauterine adhesion formation.

Eligibility criteria:
inclusion criteria: * women diagnosed with missed abortion who choose to undergo surgical evacuation. and who are at gestational age of 5+0 weeks to 11+0 weeks from last menstrual period (lmp). exclusion criteria: * women who electively choose to terminate pregnancy * women who took medical treatment for missed abortion prior to recruitment * women with known uterine abnormality
safety and efficacy assessment of autologous bone-marrow derived adult mesenchymal stem cell therapy in patients with anoxic(or hypoxic) brain injury pilot trial

Conditions: Anoxic Brain Injury

Summary: the purpose of study is to evaluate the safety and efficacy of autologous bone marrow-derived stem cells therapy in patients with anaerobic (hypoxic) brain injury. stem cell therapy is an emerging alternative treatment modality in incurable and intractable neurological disorders. this pilot study aims to evaluate the feasibility and safety of stem cells in anaerobic brain injury.

various treatment modalities to minimize the neurological deficits of anoxic brain injury, including lower consciousness, abnormal movement disorders, and abnormal behavior, have been tried, but so far there have been no effective proven method for chronic patients. this study is the investigator initiated trial to verify the safety and feasibility of stem cells therapy in patients with anoxic brain injury.

Eligibility criteria:
inclusion criteria: * patients older than 14 days after the index event occurs in an oxygen-free brain injury patients * severe disability or moderate due to anoxic brain injury * 18 years to 75 years * patients was 7 points less than glasgow coma scale (gcs) after the resumption of blood flow circulation. * anaerobic unexpected (hypoxic) cerebral ischemia encephalopathy (it should not be a hypoxic brain ischemia was induced due to heart surgery, which is scheduled) * subjects agreed in writing that it will be participating in clinical research, as viewed from the legal representative (patient) exclusion criteria: * patients who require ventilator continued * patients who had extracorporeal membrane oxygenation(ecmo) index event occurs at the time * patients who had a history of cardiac arrest prior to the occurrence of index event * end-stage people of less than 12 months is expected (incurable) disease patients * patients with cardiac arrest occurred due to brain trauma severe * patients with damage to other organs of severe * patients with bleeding or malignant current * pregnant patient * patients with central nervous system tumors undergoing radiation therapy or chemotherapy * if the patient or are participating in other clinical trials, you are planning to participate, or patients three months after the end is not passed to participate in other clinical trials

Keywords: anoxic brain injury autologous bone marrow derived stem cell stoke
severe ards: generating evidence

Conditions: Acute Respiratory Distress Syndrome; Acute Respiratory Failure With Hypoxia; Acute Respiratory Failure

Summary: an assessment of early management of moderate-severe ards in the united states, including ventilator management and use of rescue therapy.

approximately one-quarter of ards patients develop severe hypoxemia, which has been associated with mortality rates approximating 40-50%. the majority have been described to present with severe disease at baseline, suggesting an opportunity for early intervention. in addition, use of evidence-based practices in severe ards is highly variable and inconsistent; use of unproven treatment modalities is also frequently seen. given the variability in treatment practices in severe ards, an understanding of the patient-level and institutional-level factors contributing to differences in therapeutic approach is needed in order to improve the quality and consistency of care given to these high-risk patients. sage is a multicenter, observational cohort study examining the patient-level and institutional characteristics associated with variability in management of patients with moderate to severe ards, factors associated with survival or need for adjuvant therapy, and variability in ventilator management of patients on extracorporeal membrane oxygenation. findings from this observational study can subsequently be used to inform future interventional trial development.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years 2. patients with acute respiratory failure requiring invasive mechanical ventilation via an endotracheal tube or tracheostomy with current or planned admission to the icu 3. moderate-severe ards as defined by fulfillment of all of the following within 48 hours: 1. bilateral opacities detected on chest radiograph or ct, not fully explained by effusions, lung collapse, or nodules 2. respiratory failure not fully explained by cardiac failure or fluid overload 3. pao2/fio2 ratio \< 150 with a minimum of 5 cmh20 peep exclusion criteria: there are no exclusion criteria.

Keywords: acute respiratory distress syndrome ards acute lung injury ali mechanical ventilation extracorporeal membrane oxygenation neuromuscular blockade vasodilator agents prone position ecmo acute respiratory failure
a study of gaboxadol in primary insomnia

Conditions: Primary Insomnia

Summary: to evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia.

to compare hypnotic efficacy of gaboxadol with placebo in elderly outpatients with primary insomnia

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of primary insomnia

Keywords: primary insomnia
duloxetine compared with placebo in patients with generalized anxiety disorder

Conditions: Anxiety Disorders

Summary: this is a clinical trial assessing duloxetine compared with placebo in patients who have generalized anxiety disorder.


Eligibility criteria:
inclusion criteria: * male and female outpatients at least 18 years of age exclusion criteria: * have previously completed or withdrawn from this study or any other study investigating duloxetine or have previously been treated with duloxetine * patient diagnosed with major depressive disorder within the past 6 months * patient diagnosed with panic disorder, post-traumatic stress disorder, or an eating disorder within the past year * history of alcohol or any psychoactive substance abuse or dependence within the past 6 months
an assessment of the feasibility and safety of conservative oxygen therapy in critically ill patients

Conditions: Critical Illness

Summary: the investigators hypothesize that it is feasible and safe to deliver a conservative approach to oxygen therapy in mechanically ventilated critically ill patients (a tiem frame of, on average,10 days).

1. identify patients likely to require ventilation until the day after tomorrow (a time frame of 36 hours of average) 2. deliver a conservative oxygen therapy protocol while in icu (a time frame on average of 10 days) 3. target an oxygen saturation between 90 and 92% 4. adjust fio2 to achieve target sao2 at all times 5. assess percentage of time patient is within target 6. assess for safety of this approach

Eligibility criteria:
inclusion criteria: * mechanical ventilation * expected to be ventilated until the day after tomorrow (a tiem frame of, on average 48 hours) exclusion criteria: * expected to be off mechanical ventilation today or tomorrow * carbon monoxide poisoning * necrotizing fasciitis

Keywords: oxygen critical illness mechanical ventilation
pharmacokinetic and pharmacodynamic drug-drug interaction of evogliptin and empagliflozin or dapagliflozin in healthy male adults

Conditions: Type2 Diabetes

Summary: a randomized, open-label, multiple-dose, crossover study to investigate the pharmacokinetic and pharmacodynamic drug-drug interaction of evogliptin 5 mg and empagliflozin 25 mg or dapagliflozin 10 mg after oral administration in healthy male adults


Eligibility criteria:
inclusion criteria: * health male volunteers (age : 19\~55 years) * body weight≥55kg, 18.5≤bmi\<25.0 exclusion criteria: * galactose intolerance, lapp lactase deficiency, glucose-galactose malabsorption * allergy or drug hypersensitivity * clinically significant medical history * ast, alt \> upper normal range\*1.25, egfr\<60ml/min/1.73㎡ * drink during clinical trial period * smoking during clinical trial period * grapefruit/caffeine intake during clinical trial period * no contraception
transdermal buprenorphine patch for laparoscopic cholecystectomy

Conditions: Laparoscopic Cholecystectomy

Summary: preliminary studies of the transdermal buprenorphine patch target chronic pain patients, and the pain relief effect and safety have been proven. there are previous reports that the transdermal buprenorphine patch is effective in acute postoperative pain control. however, no clinical studies have yet been reported on its application during laparoscopic cholecystectomy. therefore, we designed this study to see if the use of a transdermal buprenorphine patch resulted in a better pain profile.


Eligibility criteria:
inclusion criteria: * 1) patients 19 years of age or older who are expected to undergo laparoscopic cholecystectomy 2) asa ps 1-3 exclusion criteria: * (1) patients with known hypersensitivity to buprenorphine, including patients with previous allergic contact dermatitis (2) patients with drug resistance, opioid dependence, and treatment for drug withdrawal symptoms (3) patients with severe respiratory dysfunction or respiratory depression (4) patients currently taking other central nervous system depressants or muscle relaxants that may cause respiratory depression, hypotension, severe sedation, or lead to coma (5) if you are unable to read or understand the consent form (e.g. cognitive impairment, illiteracy, foreigners, etc.) (6) other vulnerable subjects
parathyroid cancer versus atypical parathyroid neoplasm; investigating their clinical characteristics and biological behavior

Conditions: Parathyroid Carcinoma; Parathyroid Neoplasm

Summary: objectives: 1. identify the clinical characteristics of parathyroid (pth) cancer and pth atypical neoplasms 2. investigate if pth carcinoma and atypical neoplasm present a biological behaviour and have a different impact on the health of the patients

data between the years of 1/1/2002 and 12/31/2013 will be analyzed. the medical records of all adult patients that had a parathyroidectomy for primary phpt in md anderson cancer center will be screened in order to identify patients that had a histopathological diagnosis of parathyroid carcinoma or atypical parathyroid neoplasm.

Eligibility criteria:
inclusion criteria: * all patients from mdacc diagnosed with phpt that have a histopathological diagnosis of pth carcinoma or atypical parathyroid neoplasm between the years 1/1/2002 and 12/31/2013 exclusion criteria: * pediatric patients * cases with incomplete records * patients where the follow-up will be less than six months

Keywords: parathyroid carcinoma parathyroid neoplasm chart review
friends as an indicative prevention program in norway

Conditions: Anxiety

Summary: the purpose of this pilot-study is to evaluate a cognitive behavioral program, the friends-program, as indicated prevention for anxious youth. the youths are recruited by school nurses who will also lead the intervention groups applying the friends-manual.


Eligibility criteria:
inclusion criteria: * subclinical to clinical symptoms of anxiety with or without comorbid symptoms of depression exclusion criteria: * previously diagnosed with conduct disorder, major life-crises that needs to be attended to, serious school refusal, obsessive compulsive disorder, mental retardation or autism.

Keywords: open trial indicative prevention youth anxiety cognitive behavioral therapy